熱門資訊> 正文

免疫工程GAAP每股收益为-0.27美元在线

2026-08-05 19:43

Immuneering(IMRX) 0

Immuneering press release (IMRX): Q2 GAAP EPS of -$0.27 in-line.
Ended Q2 2026 with $182.7 million in cash, cash equivalents and marketable securities with anticipated runway into 2029

More on Immuneering

Immuneering: A Third (Much Cheaper) Way To Invest In The RAS-RAF-MEK-ERK 'Revolution'
Immuneering Corporation (IMRX) Discusses Positive Atebimetinib ASCO Data Update in First-Line Pancreatic Cancer Transcript
Immuneering Corporation: Updates Inbound At The End Of The Month
Seeking Alpha’s Quant Rating on Immuneering
Historical earnings data for Immuneering

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。